Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    TopAbstracts in Hypertension 11/26/2008 - (DGNews)
    Potassium Loss Caused by Thiazides May Explain Higher Risk of Adult Diabetes - (DGNews)
    High Blood Pressure in Doctor's Office May Not Predict Heart Risks - (DGNews)
    TopAbstracts in Hypertension 11/19/2008 - (DGNews)
    Aliskiren Helps Elderly Patients Achieves Blood Pressure Control: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - Hypertension
    • Minimizing Cardiovascular Risk in Patients With Dyslipidemia
    • Beta-Blockers in Hypertension - The Con Discussion
      Vaccination: A New Approach to RAAS Inhibition?
      Beta-Blockers in Hypertension - The Pro Discussion
      Which Anti-RAAS Shall We Use?

      Webcasts/CME archive

       Recent cases - Hypertension
        Aortic Dissection Type I in a Weightlifter with Hypertension: A Case Report
        Transient Left Ventricular Apical Ballooning and Exercise Induced Hypertension During Treadmill Exercise Testing: Is There a Common Hypersympathetic Mechanism?
        Dilation of Renal Artery Stenosis after Administration of Losartan
        Angioedema of the Tongue
        Primary Aldosteronism Caused by a Unilateral Adrenal Adenoma Accompanied by Autonomous Cortisol Secretion

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Nocturnal Dosing of Graded-Release Diltiazem Tops Nocturnal Ramipril for Blood Pressure Control: Presented at ASH(HYP)

        By Jill Stein

        NEW YORK, NY -- May 20, 2003 -- Nocturnal dosing of graded-release diltiazem is more effective than nocturnal dosing of ramipril in decreasing early morning blood pressure, as well as 24-hour blood pressure in patients with stage I or II hypertension.

        Researchers reported the findings here on May 16th at the 18th Annual Scientific Meeting of the American Society of Hypertension.

        William White, MD, of the University of Connecticut, Farmington, Conn, presented results in 261 patients with stage I or II hypertension. They randomized 130 patients to 10 weeks of treatment with diltiazem extended-release (240 mg to 360 mg to 540 mg QD), and 131 to ramipril (5 mg to 10 mg to 20 mg QD). Both treatments were dosed at bedtime.

        Diastolic blood pressure levels during the first 4 hours after awakening were taken in all patients with ambulatory blood pressure monitoring (ABPM), starting at baseline. Titration of the dose occurred when the clinic blood pressure was greater than or equal to 130/85 mm Hg.

        In both treatment groups, 76% of patients required titration to the highest dose, 16% only to the intermediate dose, and 8% remained on the lowest dose throughout the 10-week double-blind treatment period.

        Graded-release diltiazem was associated with a significantly larger reduction in the diastolic blood pressure during the first 4 hours after awakening, and for the 24-hour mean, compared to ramipril.

        The least squares mean difference between diltiazem extended-release and ramipril were 6.7 mm Hg (P<0.0001), 6.3 mm Hg (P<0.0001), and 2.9 mm Hg (P<0.0001), during the first 4 hours after awakening, and for the 24-hour mean, respectively.

        Diltiazem was associated with a significantly larger decrease (4.4 mm Hg, P<0.003; and 3.7 mm Hg, P<0.005) in systolic blood pressure during the first 4 hours after awakening, and for the 24-hour mean, respectively, compared to ramipril.

        Mean change from baseline in the 24-hour mean systolic blood pressure was not significantly different in either treatment group. However, qualification for randomization was based on clinic and ABPM of diastolic blood pressure, not on clinic and ABPM systolic blood pressure.

        The reductions in systolic blood pressure were larger during the first 4 hours post-awakening in patients treated with diltiazem, rather than ramipril.

        Larger reductions in ambulatory heart rate and systolic blood pressure with diltiazem led to a substantially greater change from baseline in the rate-pressure product, compared to ramipril. Rate-pressure product is a strong correlate of myocardial oxygen demand, which is a strong correlate of myocardial ischemia.

        "Both treatments were generally well tolerated, and the types and incidence of adverse events were consistent with prior reports for each treatment," Dr. White said.

        The study was supported by Biovail Corporation, Chantilly, VA.


        [Study title: Comparison of Nocturnal Dosing of Diltiazem ER And Ramipril on Early Morning Blood Pressure, Heart Rate, and the Rate-Pressure Product. Abstract P-265]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send